Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75180 | 0.87 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL74800 | 0.86 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL76826 | 0.85 | EPHX2 (0.34) | HSD11B1 | |
| SCHEMBL88689 | 0.83 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL88690 | 0.83 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL75035 | 0.80 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL75879 | 0.75 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL75880 | 0.75 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL75800 | 0.75 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL4089039 | 0.74 | HSD11B1 (0.37) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | claimed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.